Shares of Climb Bio, Inc. (NASDAQ:CLYM – Get Free Report) traded down 6.9% during trading on Monday . The company traded as low as $1.30 and last traded at $1.35. 269,172 shares traded hands during trading, a decline of 41% from the average session volume of 457,217 shares. The stock had previously closed at $1.45.
Analysts Set New Price Targets
A number of equities analysts recently commented on the stock. Leerink Partners assumed coverage on shares of Climb Bio in a research note on Monday, December 2nd. They set an “outperform” rating and a $10.00 target price for the company. Leerink Partnrs upgraded shares of Climb Bio to a “strong-buy” rating in a research note on Monday, December 2nd.
Check Out Our Latest Report on CLYM
Climb Bio Trading Down 6.9 %
About Climb Bio
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
Further Reading
- Five stocks we like better than Climb Bio
- What is the MACD Indicator and How to Use it in Your Trading
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- 3 Dividend Kings To Consider
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.
